Highlights Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 06/03/2026 GMT			5-day change	1st Jan Change
990.33 ^USD	+0.72%		-5.86%	-7.85%

03-06	Eli Lilly says CEO David A. Ricks' 2025 total compensation was $36.7 million - SEC filing	RE
03-06	Who Foundation announces collaboration with Lilly to strengthen health systems for obesity care	RE

Highlights

03-06	GoodRx Collaborates With Eli Lilly To Expand Employer-Sponsored Access To Zepbound KwikPen	CI
03-05	Eli Lilly and Company Launches Employer Connect Platform with Tailored Obesity Coverage Options	CI
03-05	Global markets live: Broadcom, Berkshire Hathaway, Morgan Stanley, Intel, Eli Lilly…
03-04	GLP-1 drugs protect against new or worsening addictions, large study shows	RE
03-04	Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others.	CI
03-04	Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis	CI
03-04	When Talk of Talks Moves Markets
03-03	Aspen Pharmacare expects Canada entry with Ozempic generic by third quarter	RE
03-03	Short war? Long war?
03-02	Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval (March 2)	RE
03-02	US asks smaller drugmakers to discuss lowering prices for Medicaid	RE
03-02	Lantheus Holdings, Inc. Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate, Radioequivalent to Lutathera	CI
02-27	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-27	Eli Lilly and Company's Olumiant Recommends by CHMP for Approval of Expanded Use in the European Union for Adolescents with Severe Alopecia Areata	CI
02-27	Eli Lilly, Incyte Say They Get EMA Panel's Positive Opinion for Olumiant to Treat Severe Alopecia Areata	MT
02-26	Eli Lilly and Company Announces Detailed Results from ACHIEVE-3	CI
02-25	RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030	MT
02-24	Pfizer Gets Full FDA Approval for Braftovi Combination for Colon Cancer Treatment	MT
02-24	A Record High for the CAC 40, Other European Indices More Cautious
02-24	Eli Lilly's Breast Cancer Drug Inluriyo Approved by UK Regulator	MT
02-24	UK Medicines Regulator OKs Eli Lilly's New Treatment for Breast Cancer	MT
02-24	UK's MHRA approves Imlunestrant Tosylate (Inluriyo) for treatment of breast cancer	RE
02-24	Barclays slashes sales forecasts for Novo's CagriSema by more than 80%	RE
02-24	Pfizer Acquires Exclusive Rights to Obesity Drug in China	DJ
02-24	US stocks end sharply lower amid AI fears, tariff angst	RE